BioSpace News Archive

Vanguard Scientific announced today the release of the Company’s formulation and Standard Operating Procedures (SOPs) for a new terpene-extract hand cleaner

Partnerships and programs address the social determinants of health across Indiana

Qventus, the leader in AI-based patient flow automation systems, today announced new Covid-19 custom planning products to help health systems forecast key resource needs both during and following the initial Covid-19 surge

As a key contributor to human health, drug-producing industries are expected to continue to operate at normal or near normal capacities despite the COVID-19 pandemic

RxMx, a global healthcare technology company that provides digital patient management, safety and adherence solutions to pharmaceutical manufacturers, is pleased to announce Covid Clear.

HALIX B.V. has joined a consortium of partners under the guidance of the University of Oxford, to provide GMP manufacturing services supporting the large scale production of a COVID-19 vaccine (ChAdOx1 nCoV-19), being developed by the University’s Jenner Institute. This GMP manufacturing scale-up is taking place alongside early phase clinical trials.

InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,715,240 shares of its common stock at a purchase price of $1.75 per share

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today reported its consolidated financial results for the fiscal ending December 31, 2019, and provided a business update.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today that, since the emergence of the COVID-19 pandemic, the company has been implementing and executing contingency plans necessary to ensure the health and safety of its employees, partners and clinical trial participants.

Company Providing Dialysis Machines to Hospitals Due to Increase in Patients with Acute Kidney Injury